The trispecific DARPin ensovibep inhibits diverse SARS-CoV-2 variants
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants with potential resistance to existing drugs emphasizes the need for new therapeutic modalities with broad variant activity. Here we show that ensovibep, a trispecific DARPin (designed ankyrin repeat protein) clinical candidate, can engage the three units of the spike protein trimer of SARS-CoV-2 and inhibit ACE2 binding with high potency, as revealed by cryo-electron microscopy analysis. The cooperative binding together with the complementarity of the three DARPin modules enable ensovibep to inhibit frequent SARS-CoV-2 variants, including Omicron sublineages BA.1 and BA.2. In Roborovski dwarf hamsters infected with SARS-CoV-2, ensovibep reduced fatality similarly to a standard-of-care monoclonal antibody (mAb) cocktail. When used as a single agent in viral passaging experiments in vitro, ensovibep reduced the emergence of escape mutations in a similar fashion to the same mAb cocktail. These results support further clinical evaluation of ensovibep as a broad variant alternative to existing targeted therapies for Coronavirus Disease 2019 (COVID-19).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
UCSF ChimeraX: Meeting modern challenges in visualization and analysis
Goddard, T. D., Huang, C. C., Meng, E. C., Pettersen, E. F., Couch, G. S., Morris, J. H., & Ferrin, T. E. (2018) · Protein Science · doi:10.1002/pro.3235 · Cited by 5,267
Structural basis of receptor recognition by SARS-CoV-2
Shang, J., Ye, G., Shi, K., Wan, Y., Luo, C., Aihara, H., Geng, Q., Auerbach, A., & Li, F. (2020) · Nature · doi:10.1038/s41586-020-2179-y · Cited by 3,661
Letko, M., Marzi, A., & Munster, V. (2020) · Nature Microbiology · doi:10.1038/s41564-020-0688-y · Cited by 3,109
Predicting the Functional Effect of Amino Acid Substitutions and Indels
Choi, Y., Sims, G. E., Murphy, S., Miller, J. R., & Chan, A. P. (2012) · PLoS ONE · doi:10.1371/journal.pone.0046688 · Cited by 2,890
Tegally, H., Wilkinson, E., Giovanetti, M., Iranzadeh, A., Fonseca, V., Giandhari, J., Doolabh, D., Pillay, S., San, E. J., Msomi, N., et al. (2020) · doi:10.1101/2020.12.21.20248640 · Cited by 2,535
Detection of a SARS-CoV-2 variant of concern in South Africa
Tegally, H., Wilkinson, E., Giovanetti, M., Iranzadeh, A., Fonseca, V., Giandhari, J., Doolabh, D., Pillay, S., San, E. J., Msomi, N., et al. (2021) · Nature · doi:10.1038/s41586-021-03402-9 · Cited by 2,510
Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7
Wang, P., Nair, M. S., Liu, L., Iketani, S., Luo, Y., Guo, Y., Wang, M., Yu, J., Zhang, B., Kwong, P. D., et al. (2021) · doi:10.1101/2021.01.25.428137 · Cited by 2,328
Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7
Wang, P., Nair, M. S., Liu, L., Iketani, S., Luo, Y., Guo, Y., Wang, M., Yu, J., Zhang, B., Kwong, P. D., et al. (2021) · Nature · doi:10.1038/s41586-021-03398-2 · Cited by 2,312
Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies
Cao, Y., Wang, J., Jian, F., Xiao, T., Song, W., Yisimayi, A., Huang, W., Li, Q., Wang, P., An, R., et al. (2022) · Nature · doi:10.1038/s41586-021-04385-3 · Cited by 2,006
Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization
Planas, D., Veyer, D., Baidaliuk, A., Staropoli, I., Guivel-Benhassine, F., Rajah, M. M., Planchais, C., Porrot, F., Robillard, N., Puech, J., et al. (2021) · Nature · doi:10.1038/s41586-021-03777-9 · Cited by 1,992
Cited by
Zhou, H., Dcosta, B. M., Samanovic, M. I., Mulligan, M. J., Landau, N. R., & Tada, T. (2021) · mBio · doi:10.1128/mbio.01386-21 · Cited by 68
Castells-Graells, R., Meador, K., Arbing, M. A., Sawaya, M. R., Gee, M., Cascio, D., Gleave, E., Debreczeni, J. É., Breed, J., Leopold, K., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2305494120 · Cited by 48
Umbaugh, C. S., Groth, M., Erkut, C., Lee, K.-S., Marinho, J., Linder, S., Iser, F., Kapp, J. N., Schroeter, P., Dolaner, S., et al. (2025) · Science Advances · doi:10.1126/sciadv.adu2796 · Cited by 6
Exploiting the Affimer platform against influenza A virus
Debski-Antoniak, O., Flynn, A., Klebl, D. P., Rojas Rechy, M. H., Tiede, C., Wilson, I. A., Muench, S. P., Tomlinson, D., & Fontana, J. (2024) · mBio · doi:10.1128/mbio.01804-24 · Cited by 3
Metadata
- Authors
- Rothenberger, S., Hurdiss, D. L., Walser, M., Malvezzi, F., Mayor, J., Ryter, S., Moreno, H., Liechti, N., Bosshart, A., Iss, C., Calabro, V., Cornelius, A., Hospodarsch, T., Neculcea, A., Looser, T., Schlegel, A., Fontaine, S., Villemagne, D., Paladino, M., Schiegg, D., Mangold, S., Reichen, C., Radom, F., Kaufmann, Y., Schaible, D., Schlegel, I., Zitt, C., Sigrist, G., Straumann, M., Wolter, J., Comby, M., Sacarcelik, F., Drulyte, I., Lyoo, H., Wang, C., Li, W., Du, W., Binz, H. K., Herrup, R., Lusvarghi, S., Neerukonda, S. N., Vassell, R., Wang, W., Adler, J. M., Eschke, K., Nascimento, M., Abdelgawad, A., Gruber, A. D., Bushe, J., Kershaw, O., Knutson, C. G., Balavenkatraman, K. K., Ramanathan, K., Wyler, E., Teixeira Alves, L. G., Lewis, S., Watson, R., Haeuptle, M. A., Zürcher, A., Dawson, K. M., Steiner, D., Weiss, C. D., Amstutz, P., van Kuppeveld, F. J. M., Stumpp, M. T., Bosch, B.-J., Engler, O., & Trimpert, J.
- Venue
- Nature Biotechnology
- Published
- 2022-07-21
- Volume
- 40
- Issue
- 12
- Pages
- 1845-1854
- ISSN
- 0733-222X (ISSN-L)
- 1087-0156
- 1546-1696
- OpenAlex
- W4286493109
- Cited by
- 57
- References
- 40
- FWCI
- 5.90
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The trispecific DARPin ensovibep inhibits diverse SARS-CoV-2 variants. https://app.cochat.ai/papers/10.1038/s41587-022-01382-3
- The paper
- Rothenberger, S., Hurdiss, D. L., Walser, M., Malvezzi, F., Mayor, J., Ryter, S., Moreno, H., Liechti, N., Bosshart, A., Iss, C., Calabro, V., Cornelius, A., Hospodarsch, T., Neculcea, A., Looser, T., Schlegel, A., Fontaine, S., Villemagne, D., Paladino, M., . . . Trimpert, J. (2022). The trispecific DARPin ensovibep inhibits diverse SARS-CoV-2 variants. Nature Biotechnology. https://doi.org/10.1038/s41587-022-01382-3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.